Construction of an expression platform for fungal secondary metabolite biosynthesis in Penicillium crustosum
Applied Microbiology and Biotechnology · 2024
DOI: 10.1007/s00253-024-13259-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Applied Microbiology and Biotechnology, 2024. Verfasst von Jenny Zhou und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institut Für Pharmazeutische Biologie Und Biotechnologie, Fachbereich Pharmazie, Philipps-Universität Marburg, Robert-Koch-Straße 4, 35037, Marburg, …. Hauptthemen laut MEDLINE: Penicillium, Secondary Metabolism, CRISPR-Cas Systems. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Chinese Government Scholarship, Marburg University Research Academy.
Abstract (Originalsprache)
Filamentous fungi are prolific producers of bioactive natural products and play a vital role in drug discovery. Yet, their potential cannot be fully exploited since many biosynthetic genes are silent or cryptic under laboratory culture conditions. Several strategies have been applied to activate these genes, with heterologous expression as one of the most promising approaches. However, successful expression and identification of new products are often hindered by host-dependent factors, such as low gene targeting efficiencies, a high metabolite background, or a lack of selection markers. To overcome these challenges, we have constructed a Penicillium crustosum expression host in a pyrG deficient strain by combining the split-marker strategy and CRISPR-Cas9 technology. Deletion of ligD and pcribo improved gene targeting efficiencies and enabled the use of an additional selection marker in P. crustosum . Furthermore, we reduced the secondary metabolite background by inactivation of two highly expressed gene clusters and abolished the formation of the reactive ortho -quinone methide. Finally, we replaced the P. crustosum pigment gene pcr4401 with the commonly used Aspergillus nidulans wA expression site for convenient use of constructs originally designed for A. nidulans in our P. crustosum host strain. As proof of concept, we successfully expressed a single polyketide synthase gene and an entire gene cluster at the P. crustosum wA locus. Resulting transformants were easily detected by their albino phenotype. With this study, we provide a highly efficient platform for heterologous expression of fungal genes. Key points Construction of a highly efficient Penicillium crustosum heterologous expression host Reduction of secondary metabolite background by genetic dereplication strategy Integration of wA site to provide an alternative host besides Aspergillus nidulans Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut Für Pharmazeutische Biologie Und Biotechnologie, Fachbereich Pharmazie, Philipps-Universität Marburg, Robert-Koch-Straße 4, 35037, Marburg, Germany.
- Institut Für Pharmazeutische Biologie Und Biotechnologie, Fachbereich Pharmazie, Philipps-Universität Marburg, Robert-Koch-Straße 4, 35037, Marburg, Germany. shuming.li@staff.uni-marburg.de.
Förderung
- Deutsche Forschungsgemeinschaft
- Chinese Government Scholarship
- Marburg University Research Academy
- Philipps-Universität Marburg
Zitieren
APA
Zhou, J., Chen, X., & Li, S. M. (2024). Construction of an expression platform for fungal secondary metabolite biosynthesis in Penicillium crustosum. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-024-13259-3
Vancouver
Zhou J, Chen X, Li SM. Construction of an expression platform for fungal secondary metabolite biosynthesis in Penicillium crustosum. Applied Microbiology and Biotechnology. 2024. doi:10.1007/s00253-024-13259-3
BibTeX
@article{Zhou2024,
author = {Zhou, Jenny and Chen, Xiaoling and Li, Shu-Ming},
title = {Construction of an expression platform for fungal secondary metabolite biosynthesis in Penicillium crustosum},
journal = {Applied Microbiology and Biotechnology},
year = {2024},
doi = {10.1007/s00253-024-13259-3}
}
EUVIMED